PNPLA8

Across TCGA pan-cancer cohorts, PNPLA8 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PNPLA8 data layer compared with 23 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PNPLA8 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PNPLA8 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where PNPLA8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.628	0.903	.016	10	view →
HNSC	DFS	Median	All	0.982	0.901	.005	7	view →
PDAC	DFS	Quartile	II,III,IV	0.922	0.712	.004	6	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	4	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PNPLA8–CCRCC (DFS)

Open the CCRCC breakdown →